Article Text

Download PDFPDF
Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials
  1. Maxime MA Verhoeven1,
  2. Marjolein JH de Hair1,
  3. Janneke Tekstra1,
  4. Johannes WJ Bijlsma1,
  5. Jacob M van Laar1,
  6. Attila Pethoe-Schramm2,
  7. Michelle EA Borm3,
  8. Evert-Jan ter Borg4,
  9. Suzanne P Linn-Rasker5,
  10. Xavier M Teitsma1,
  11. Floris PJG Lafeber1,
  12. Johannes WG Jacobs1,
  13. Paco MJ Welsing1
  1. 1 Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands
  2. 2 ACTEMRA/Rheumatology, F Hoffmann-La Roche AG, Basel, Switzerland
  3. 3 Rheumatology, Roche Nederland BV, Woerden, The Netherlands
  4. 4 Department of Rheumatology, Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands
  5. 5 Department of Rheumatology, Meander Medical Centre, Amersfoort, The Netherlands
  1. Correspondence to Maxime MA Verhoeven, Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht 3508 GA, The Netherlands; m.m.a.verhoeven-15{at}umcutrecht.nl

Footnotes

  • Handling editor Josef S Smolen

  • Contributors PMJW, MMAV and MJHdH contributed to study design, data cleaning and data analysis. All authors contributed to data interpretation, writing of the report, revising it critically and approved the final version to be published and agree to be accountable for all aspects.

  • Funding The U-Act-Early trial was funded by Roche Nederland BV, and the CAMERA-II trial was financially supported by the Catharijne Foundation (grant 20063).

  • Competing interests JWJB reports grants and fees from Roche, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer and UCB. JMvL reports grants from Arthrogen, grants from MSD, personal fees from Pfizer, personal fees from Eli Lilly, personal fees from BMS, grants from Astra Zeneca and grants from Roche-Genentech. AP-S is an employee of F Hoffmann-La Roche. MEAB is an employee of Roche Netherlands BV. FPJL reports grants from Roche.

  • Patient consent for publication Not required.

  • Ethics approval The medical ethics research committee of the University Medical Center Utrecht approved both studies (U-Act-Early and CAMERA-II) with subsequent sanctioning of all participating hospitals. Study ID number: ML28388 and NHMRC1078930.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No data are available.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • Contributors PMJW, MMAV and MJHdH contributed to study design, data cleaning and data analysis. All authors contributed to data interpretation, writing of the report, revising it critically and approved the final version to be published and agree to be accountable for all aspects.

  • Funding The U-Act-Early trial was funded by Roche Nederland BV, and the CAMERA-II trial was financially supported by the Catharijne Foundation (grant 20063).

  • Competing interests JWJB reports grants and fees from Roche, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer and UCB. JMvL reports grants from Arthrogen, grants from MSD, personal fees from Pfizer, personal fees from Eli Lilly, personal fees from BMS, grants from Astra Zeneca and grants from Roche-Genentech. AP-S is an employee of F Hoffmann-La Roche. MEAB is an employee of Roche Netherlands BV. FPJL reports grants from Roche.

  • Patient consent for publication Not required.

  • Ethics approval The medical ethics research committee of the University Medical Center Utrecht approved both studies (U-Act-Early and CAMERA-II) with subsequent sanctioning of all participating hospitals. Study ID number: ML28388 and NHMRC1078930.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.